CTGF

CTGF

CTGF Overview

Molecule Name
Connective tissue growth factor
Synonyms
CCN2,NOV2,HCS24,IGFBP8,IBP-8,IGFBP-8,IGF-binding protein 8
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs1
Highest Development StageApproved
Target Synonym
Cellular communication network factor 2,IBP-8,Hypertrophic chondrocyte-specific protein 24,IGF-binding protein 8,IGFBP-8,Connective tissue growth factor,IGFBP8,CCN2,Insulin-like growth factor-binding protein 8,HCS24,CCN family member 2,CTGF,NOV2
Background
Connective Tissue Growth Factor (CTGF), also known as CCN2, is a member of the CCN (CCN1-6) family of modular matricellular proteins. Like other CCN proteins, mature human CTGF consists of IGF-binding protein domain, a vWF-C domain, a TSP-1 domain, and a cysteine knot heparin-binding domain. CTGF promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Analysis of CCN2 function in vivo has focused primarily on its key role as a mediator of excess ECM synthesis in multiple fibrotic diseases.

CTGF Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
PamrevlumabFG-3019Phase 3 ClinicalFibrogen Inc
Coronavirus Disease 2019 (COVID-19); Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerulosclerosis, Focal Segmental; Idiopathic Pulmonary Fibrosis; Liver Cirrhosis; Muscular Dystrophy, Duchenne; Pancreatic Neoplasms
Details
OLX-10010cp-asiCTGF; OLX-101A; OLX-10010; BMT-101; OLX-101Phase 2 ClinicalOlix Pharmaceuticals Inc
Cicatrix, Hypertrophic; Macular Degeneration; Pulmonary Fibrosis; Wet Macular Degeneration
Details
SHR-1906SHR-1906Phase 2 ClinicalGuangdong Hengrui Pharmaceutical Co Ltd
Idiopathic Pulmonary Fibrosis
Details
PRS-220PRS-220Phase 1 ClinicalPieris Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Details
LEM-S401LEM-S401; LEMS401Phase 1 ClinicalLemonex Inc
Cicatrix
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PenicillamineApprovedValeantDistamine, Pemine, Trisorcin, Cuprimine, Cupramine, TrolovolUnited StatesArthritis, Rheumatoid; Hepatolenticular Degeneration; CystinuriaBausch Health Companies Inc1970-12-04
Arthritis, Rheumatoid; Cystinuria; Heavy Metal Poisoning; Hepatolenticular Degeneration; Lead Poisoning
Details